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Abstract
Purpose To evaluate the prognostic value of substaging on oncological outcomes in patients with T (or pT1) urothelial 
carcinoma of the bladder.
Methods A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on March 2019 
to identify relevant studies according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) 
guidelines. The pooled disease recurrence (DR) and disease progression (DP) rate in T1(or pT1) patients were calculated 
using a fixed or random effects model.
Results Overall 36 studies published between 1994 and 2018 including a total of 6781 bladder cancer patients with T1(or 
pT1) stage were selected for the systematic review and meta-analysis. Twenty-nine studies reported significant association 
between tumor infiltration depth or muscularis mucosa (MM) invasion and oncological outcomes. Totally 12 studies were 
included in the meta-analysis. MM invasion (T1a/b/c [or pT1a/b/c] or T1a/b [or pT1a/b] substaging system) was associated 
with DR (pooled HR: 1.23, 95%CI: 1.01–1.49) and DP (pooled HR: 2.61, 95%CI: 1.61–4.23). Tumor infiltration depth 
(T1 m/e [or pT1 m/e] substaging system) was also associated with DR (pooled HR: 1.49, 95%CI: 1.11–2.00) and DP (pooled 
HR: 3.29, 95%CI: 2.39–4.51).
Conclusions T1(or pT1) substaging in patients with bladder cancer is of prognostic value as it is associated with oncologic 
outcomes. Inclusion of this factors into the clinical decision-making process of this heterogeneous tumor may improve out-
comes, while avoiding over- and under-treatment for T1(or pT1) bladder cancer.
Keywords Staging · Substage · pT1 · T1 · Bladder cancer · Progression · Prognosis · Urothelial carcinoma
Introduction
T1 carcinoma of the urinary bladder is a heterogeneous dis-
ease with potentially aggressive behavior leading to lethality 
[1]. Indeed, despite sharing many of the genetic and epige-
netic factors of muscle-invasive bladder cancer, it is classi-
fied as non-muscle invasive. Yet, patients with T1 bladder 
cancer have an overall mortality of 33% and a cancer-spe-
cific mortality of 14% at three years after diagnosis, suggest-
ing that these patients have a high risk of disease progression 
and, accordingly, require meticulous surgery, endoscopic 
surveillance and informed clinical decision-making [2].
The variability in the outcomes of patients with T1 blad-
der cancer is a result of both tumor heterogeneity and patho-
logical staging, as well as inconsistencies in risk stratifica-
tion, endoscopic resection and schedules of delivery of BCG 
[3]. Owing to limitations in clinical staging, patients with 
T1 bladder cancer are at risk of both under-treatment with 
use of BCG despite recurrence, and overtreatment with early 
radical cystectomy. Understanding the pathologic features 
of T1 bladder cancers and how they impact prognosis and, 
therefore, could improve risk stratification to align therapy 
with biological risk and clinical behavior of the individual 
tumor [4, 5]. While novel prognostic features such as variant 
histology and lymphovascular invasion have been included 
 * Shahrokh F. Shariat 
 sfshariat@gmail.com
Extended author information available on the last page of the article
1438 World Journal of Urology (2020) 38:1437–1449
1 3
in the clinical decision-making, more features are needed to 
improve our prognostic accuracy [5–7].
There is a growing evidence that tumor depth and exten-
sion could be such a feature for patients with T1(or pT1) 
bladder cancer [8, 9]. To test this hypothesis, we performed a 
systematic review and meta-analysis to evaluate the value of 
T1(or pT1) substaging for predicting oncological outcomes 
in patients with T1(or pT1) urothelial carcinoma of the blad-
der. T1 and pT1 were referred to disease stage in patients 
who underwent trans-urethral resection of bladder tumor 
(TURBT) and radical cystectomy, respectively.
Materials and methods
Search strategy
A full electronic literature search using PubMed, Scopus, 
Web of Science, and Cochrane Library was conducted by 
two independent authors on March 2019 to find relevant 
studies for this systematic review and meta-analysis accord-
ing to the Preferred Reporting Items for Systematic Review 
and Meta-analysis (PRISMA) guidelines [10]. The search 
terms used were (“T1” OR “T1a” OR “T1b” OR “T1 m” 
OR “T1e” OR “muscularis mucosa invasion” OR “subclas-
sification” OR “substage” OR “substaging”) AND (“bladder 
cancer” OR “bladder carcinoma” OR “bladder neoplasm”). 
The protocol for this systematic review was registered in 
PROSPERO (Prospective Register of Systematic Reviews, 
CRD42019129661) and is available in full on the University 
of York website.
Inclusion criteria
The following criteria were considered to select eligible 
studies: prospective or retrospective studies including full 
text regarding T1(or pT1) substaging in patients with non-
muscle-invasive bladder cancer (NMIBC) with oncological 
outcomes including disease recurrence (DR) and disease 
progression (DP). We excluded studies in other than Eng-
lish, meeting abstract, case reports, review articles, replies, 
expert opinions, and comment letters.
Data extraction
Data were extracted on first author, year of publication, 
patients, region of study, recruitment period, study design, 
total number of T1(or pT1) patients, number of substaged 
T1(or pT1) patients, substaging system, patients’ age, and 
follow-up duration. Oncological outcomes including DR 
and DP were the primary outcomes of interest. DR was 
defined as histological detection of bladder cancer and DP 
was defined as development of muscle-invasive disease or 
distant metastasis after primary treatment. Two independent 
reviewers assessed all full text studies and excluded inap-
propriate ones after screening based on the study title and 
abstract. The muscularis mucosa (MM) invasion substaging 
was defined as T1a/b (or pT1a/b) or T1a/b/c (or pT1a/b/c). 
According to the T1a/b (or pT1a/b) staging, T1a (or pT1a), 
where tumors cells invade the lamina propria but are still 
located above the level of the MM and T1b (or pT1b), where 
tumors cells are seen invading into or beyond the MM. In 
T1a/b/c (or pT1a/b/c) staging system, T1a (or pT1a) was 
defined as invasion into the stroma but not to MM, T1b (or 
pT1b); invasion into MM but not beyond MM, and pT1c 
(or pT1c); invasion beyond the MM but not to muscularis 
propria. Infiltration depth substaging system was defined as 
T1 m/e (or pT1 m/e). T1 m, or pT1 m (micro infiltration) 
was a single focus of lamina propria invasion with a maxi-
mum depth of 0.5 mm (within one high power field; objec-
tive × 40). T1e or pT1/e (extensive infiltration) was defined 
as a larger area with invasion or multiple micro-invasive 
areas.
Statistical analyses
We extracted reported HRs and 95%CIs to calculate cumu-
lative effect size of studies which presented the association 
between T1(or pT1) substaging and DR and DP. Studies 
presented HR using multivariate Cox proportional hazard 
regression model were included in meta-analysis. STATA/
MPTM, version 14.2 (Stata-Corp., College Station, TX, 
USA) was used to perform meta-analysis. Heterogene-
ity between the studies included in the meta-analysis was 
assessed by Cochrane Q test and  I2 statistics. An  I2 > 50% 
and p value < 0.05 in Cochrane Q test implied that the het-
erogeneity existed. With no heterogeneity among selected 
studies, we considered fixed effect models to calculate 
pooled HRs. In case of significant heterogeneity, we used 
random effect model. Visual inspection of funnel plot was 
carried out to identify publication bias in our meta-analysis.
Risk of bias (RoB) assessment
The RoB assessment of each study was done according to 
the Cochrane Handbook for Systematic Reviews of Interven-
tions for including nonrandomized studies [11, 12]. The con-
founding factors including treatment modality, tumor grade, 
carcinoma in situ (CIS), multifocality, T1 (or pT1) substag-
ing, and tumor size were identified as the most important 
prognostic factors. The presence of confounders was deter-
mined by consensus. The RoB assessment for each study was 
performed by two independent authors and the overall RoB 
level was presented as “low”, “intermediate”, or “high” risk.




A total of 4999 studies were found after an initial search; 
3036 records remained after exclusion of duplicates (Fig. 1). 
After exclusion of non-relevant studies, review articles, case 
reports, comments, replies, meeting abstracts, and studies in 
other than English, 57 studies remained. Finally, 36 and 12 
studies were included for qualitative and quantitative evi-
dence synthesis, respectively.
Characteristics of the included studies
Tables 1 and 2 summarize the studies’ characteristics and 
patients’ clinical data, respectively. Four studies were 
designed prospectively [13–16] and 32 studies were ret-
rospective in design [8, 9, 17–46]. All studies were pub-
lished between 1994 and 2018. In total, 6781 patients were 
included in 36 studies with 5964 patients who underwent T1 
(or pT1) substaging and outcomes analysis. Twenty-three 
studies came from Europe, five from North America, six 
from Asia, and two from Europe/Canada region.
Nine studies included patients who had been substaged 
with both MM and tumor infiltration depth staging systems. 
Twenty-two studies included MM invasion substaging sys-
tem only and five included patients substaged with tumor 
infiltration depth staging system only. TURBT with or with-
out intravesical BCG or chemotherapy agents was reported 
as initial therapy in 6677 patients. Radical or partial cystec-
tomy and/or radiation therapy were reported in 104 patients 
as initial therapeutic modality [13, 17, 24, 29, 35, 39, 45]. 
The prognostic value of T1(or pT1) substaging on at least 
one oncological outcome was established in 29 studies.
Meta‑analysis
T1 (or pT1) MM invasion substaging and DP
The impact of MM invasion on DP was investigated in 
patients with T1(or pT1) bladder urothelial carcinoma. Over-
all seven studies with a total of 899 patients were identi-
fied and MM invasion was associated with a higher DP rate 
Fig. 1  PRISMA flow chart 
for article selection process to 
analyze the prognostic value 
of T1 substaging on oncologi-
cal outcomes in patients with 
non-muscle-invasive bladder 
urothelial carcinoma
Records idenfied through MEDLINE, Web of Science, Scopus
And Cochrane Library:
Search Query: 
((T1 OR T1a OR T1b OR T1m OR T1e OR muscularis mucosa invasion OR 
subclassificaon OR substage OR substaging)) AND (bladder cancer OR bladder 





Records screened aer 
duplicates removed
(n =3,036)
Records excluded aer tle and abstract 
review (2,979)
Non-relevant according to inclusion criteria (2951)




Other than English language (6)Full-text arcles assessed 
for eligibility
(n = 57 )
Arcles excluded aer evaluaon 
(n =21)
Non-clear data regarding associaon between T1 
substaging and oncological outcomes
Studies included in this systemac 
review
(n =36)
Studies included in this meta-analysis
(n = 12)
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Table 1  Study characteristics of 40 studies assessing the prognostic value of T1 substaging in patients with bladder urothelial carcinoma
Author Year Region Recruitment 
period







Hasui [23] 1994 Japan 1980–1991 Retrospective 88 88 MM invasion 
(T1a/T1b)
DR, DP
Holmäng [24] 1997 Sweden 1987–1988 Retrospective 121 113 MM invasion 
(T1a/T1b)
DP, CSS, OS
Smits [40] 1998 The Netherlands 1987–1990 Retrospective 133 124 MM invasion 
(T1a/T1b/T1c)
DR, DP
Cheng [22] 1999 USA 1987–1992 Retrospective 83 83 Depth of lamina 
propria invasion
DP
Kondylis [26] 2000 USA 1981–1997 Retrospective 55 49 MM invasion 
(T1a/T1b)
DR, DP
Shariat [39] 2000 USA N/A Retrospective 47 36 MM invasion 
(T1a/T1b)
DR, DP, OS
Bernardini [17] 2001 France 1973–1996 Retrospective 149 94 MM invasion 
(T1a/T1b)
PFS
Sozen [42] 2002 Turkey 1983–1997 Retrospective 90 50 MM invasion 
(T1a/T1b)
DR, DP
Orsola [32] 2005 Spain 1996–2001 Retrospective 97 85 MM invasion 
(T1a/T1b/T1c)
RFS, PFS




















2007 Spain 1986–2003 Retrospective 91 83 MM invasion 
(T1a/T1b)
DP
Soukup [16] 2008 Czech Republic 2001–2005 Prospective 105 99 MM invasion 
(T1a/T1b)
DR, DP (PFS)
Orsola [14] 2010 Spain N/A Prospective 159 138 MM invasion 
(T1a/T1b)
DR, DP
Bertz [18] 2011 Germany 1989–2006 Retrospective 309 309 MM invasion 
(T1a/T1b), 
Infiltration 
depth (≤ 1 
HPF/> 1 HPF)
CSS, RFS, PFS
Palou [34] 2012 Spain/Belgium 1985–1996 Retrospective 146 93 MM invasion 
(T1a/T1b/T1c)
DR, DP, CSM
Lee [27] 2012 Korea 1999–2009 Retrospective 183 183 MM invasion 
(T1a/T1b/T1c)
DR, DP, CSM
Chang [21] 2012 Taiwan 1991–2005 Retrospective 509 509 Muscularis 
mucosa inva-
sion, Infiltra-
tion depth (3 
cut-off values 
to substage 




DR, DP, CSD, OM
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Table 1  (continued)
Author Year Region Recruitment 
period







van Rhijn [46] 2012 The Netherlands/
Canada












Olsson [31] 2013 Sweden 1992–2001 Retrospective 285 211 MM invasion 
(T1a/T1b/T1c)
DR, DP




Rouprêt [38] 2013 France 1994–2010 Retrospective 612 587 MM invasion 
(T1a/T1b)
RFS, PFS, CSS
Soukup [41] 2014 Czech Republic 2002–2009 Retrospective 200 176 MM invasion 
(T1a/T1b)
RFS, PFS, CSS, 
OS
Hu [25] 2014 USA 1997–2005 Retrospective 39 23 Focality, Percent-












Lim [28] 2015 Korea 1998–2012 Retrospective 177 141 MM invasion 
(T1a/T1b/T1c)
RFS, PFS
Orsola [15] 2015 Spain N/A Prospective 200 200 MM invasion 
(T1a/T1b)
DR, DP
Patschan [36] 2015 Sweden 1997–2003 Retrospective 167 152 MM invasion 
(T1a/T1b/T1c)
PFS
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(pooled HR 2.61, 95%CI: 1.61–4.23) (Fig. 2A) [16, 19, 27, 
28, 32, 41, 46]. A statistically significant heterogeneity was 
found among included studies using the Chi-square and I2 
tests (I^2 = 54.1%, p = 0.042); the weights were from random 
effect model to analyze pooled HR. Funnel plots identified 
one study over the pseudo 95%CI (Fig. 2A).
T1 (or pT1) MM invasion substaging and DR
Six studies in a total of 930 patients reported HR to present 
the prognostic value of MM invasion on DR in T1(or pT1) 
urothelial bladder carcinoma patients [16, 18, 19, 27, 40, 
46]. The overall pooled HR was 1.23 (95%CI: 1.01–1.49) 
implying a significant association between MM invasion and 
DR (Fig. 2A). The Chi-square and I2 tests did not show any 
significant heterogeneity (I^2 = 41.4%, p = 0.129). Funnel 
plots revealed one study over the pseudo 95%CI (Fig. 2A). 
Figure 2B shows the RoB table of studies included in the 
T1(or pT1) MM invasion substaging meta-analysis.
Infiltration depth substaging and DP
Five studies with a total of 1171 patients with T1(or pT1) 
bladder urothelial carcinoma reported the association of 
tumor infiltration depth and DP [9, 18, 30, 45, 46]. Tumor 
infiltration depth was associated with DP (pooled HR: 3.29, 
95%CI: 2.39–4.51) (Fig. 3A). There was no significant 
heterogeneity in the Cochrane Q or I2 tests (I^2 = 0.0%, 
p = 0.924). No study was detected over the pseudo 95%CI 
on Funnel plots (Fig. 3A).
Infiltration depth substaging and DR
The impact of infiltration depth on DR was investigated 
in three studies in a total of 517 patients with T1(or pT1) 
bladder urothelial carcinoma [18, 30, 46]. There was a sig-
nificant association between infiltration depth and DR with 
pooled HR of 1.49 (95%CI: 1.11–2.00) (Fig. 3A). The Chi-
square and I2 tests did not show any significant heterogeneity 
(I^2 = 56.4%, p = 0.101). Funnel plots identified no study 
over the pseudo 95%CI (Fig. 3A). Figure 3B shows the RoB 
table of studies included in T1(or pT1) Infiltration depth 
substaging meta-analysis.
Discussion
In this systematic review and meta-analysis, we assessed 
the prognostic value of T1(or pT1) substaging systems on 
oncological outcomes in patients with T1(or pT1) blad-
der urothelial carcinoma. Both MM invasion and tumor 
infiltration depth substaging systems were strongly associ-
ated with both DR and DP after adjusting for the effects of 
established confounding factors (e.g., tumor grade, CIS, and 
multifocality).
Table 1  (continued)
Author Year Region Recruitment 
period







Fransen van de 
Putte [9]





tration of LP 
(T1 m/T1e)
PFS, CSS
Otto [33] 2018 Germany/The 
Netherlands











N/A not available, LP lamina propria, MM muscularis mucosa, PFS progression-free survival, CSM cancer-specific mortality, CSS cancer-spe-
cific survival, OS overall survival, WFS worsening-free survival, DR disease recurrence, DP disease progression, RFS recurrence-free survival, 
OM overall mortality, HPF high power field
† ROL substaging ROL1 < 1 power field (objective 20×, ocular 10×/field 22, diameter 1.1 mm) of invasion, approximately corresponding to inva-
sion of the lamina propria 1 mm thick or less; ROL2: > 1 power field (objective 20×), approximately corresponding to invasion of the lamina 
propria more than 1 mm thick, or multifocal invasion with foci cumulatively amounting to invasion of the lamina propria more than 1 mm thick
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Table 2  Patient characteristics in 40 studies assessing the prognostic role of T1 substaging in patients with bladder urothelial carcinoma
N/A not available, S significant, NS non-significant, MM muscularis mucosa PFS progression-free survival, CSM cancer-specific mortality, CSS 
cancer-specific survival, OS overall survival, OM overall mortality, DR disease recurrence, DP disease progression, RFS recurrence-free sur-
vival, HPF high power field
† S statistical significance p value < 0.05
Author Age, year (range) Independent correlation with oncologic 
outcomes
Follow-up duration
Hasui [23] Mean: 68 (37–95) S N/A
Holmäng [24] Mean: 73.1 (48–97) S (for DP and CSS) ≥ 5 years
Smits [40] N/A S (for PFS) Minimal follow-up: 3 years
Cheng [22] Mean: 71 (47–94) S Mean: 5.2 years (range, 1 day–10.4)
Kondylis [26] N/A NS Median 71 months (range, 4–147)
Shariat [39] Median: 67 (30–86) NS Median: 79 months
Bernardini [17] Mean: 68.9 (42–90) S Mean: 64.9 months (range, 5–288)
Sozen [42] Median: 62 (33–84) S Mean: 68 months (range, 24–120)
Orsola [32] Mean: 66.4(30.3–86.8) S (in T1b/c vs T1a substaging for RFS and 
PFS)
Mean: 53 months
van der Aa [45] Mean: 68 (47–90) S Median: 55 months (range, 9–228)
Chaimuangraj [20] Mean: 60 (43–83) S N/A
Andius [13] Median: 74 (48–98) NS Median: 15 years for alive cases
Mhawech-Fauceglia [29] Mean: 70 S (for DP) Median: 12 months
Queipo-Zaragoza [37] Mean: 68.1 S Mean: 57.8 months (range, 13–24)
Soukup [16] Mean: 68.43 (38–87) S (for PFS) Mean: 23.31 months
Orsola [14] Mean: 69 S (for DP) Median: 20.3 months
Bertz [18] Median: 71.7 (38–87 years). S (in Infiltration depth: ≤ 1 HPF vs > 1 HPF 
for RFS and PFS)
Mean: 49 months (range, 5–172)
Palou [34] Mean: 64.9 (25–81) NS Median: 8.7 years
Lee [27] Mean: 63.5 years (27–93) S (for DP and CSM) Mean: 43.5 months (range, 12–146)
Chang [21] Mean: 71 (23–92) S (MM invasion: S for DP, CSM, and OM) 
(depth of high-grade tumor: S for DR, DP, 
CSM, OM)
Mean: 88 months (range, 1–240) for 
patients who were alive
Mean: 39 months (range, 1–193) for 
patients who died
van Rhijn [46] Mean: 68.8 S (in T1 m/T1e for DP) Median: 6.5 years
Brimo [19] Mean: 71 S Mean: 29 months
Olsson [31] Median: 74 S (in T1b/c vs T1a substaging for DP in 
patients older than 73 years)
Median: 60 months
Nishiyama [30] Mean: 68.5 S (for DR) Mean: 74.0 months
Rouprêt [38] Median: 70 S Mean: 44 months (range, 6–161)
Soukup [41] Median: 68.83 (17.55–86.94) S (for PFS, CSS, OS) Median: 3.13 years (0.1–10.5)
Hu [25] Mean: 70 years (56–94) S (in aggregate length of invasion; > 0.5 cm) N/A
D. E. Marco [44] Mean: 69.9 NS Median: 9.5 years
Lim [28] Mean: 68.9 (20–93) S (for PFS) Mean: 73.3 months (range, 3.9–187.9)
Orsola [15] Median: 71 S (for DP) Median: 71 months (range: 5–107)
Patschan [36] Median: 74 NS (3 years follow-up in analysis)
Patriarca [35] Mean: 71.3 (64–79) S (in ROL1 VS ROL 2 substaging for DP) Mean: 46 months
Colombo [8] Mean: 70 (64–77) S (for DP in ROL2 vs ROL1 substaging) Median: of 60 months
Fransen van de Putte [9] Median: 71 S (for PFS and CSS in T1e vs T1 m substag-
ing)
Median: 5.9 years
Otto [33] Median: 72 NS Median: 42 months
Turan [43] Mean: 67.9 S (in T1a/b substaging for DR) Mean: 54 months
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The most widely used prognostic tools, taking into 
account tumor grade and stage, prior recurrences, tumor 
size, multifocality, and the presence of CIS, are still subop-
timal to predict DR and DP. Moreover, the lack of effective 
bladder cancer information among general public may be as 
an important factor affecting patients’ outcomes and online 
information and social media could be effective to improve 
quality of patient’s care and disease management in patients 
with bladder cancer [47].
We and others have shown that the current prognostic and 
risk stratification tools are too inaccurate to guide clinical 
decision making safely [1, 48, 49]. In this review and meta-
analysis, we confirm that tumor invasion into MM and tumor 
infiltration depth of more than 0.5 mm are strong predictors 
of disease recurrence and progression and could be used to 
distinguish high risk patients for recurrence and progres-
sion who might benefit from standard adjuvant therapy (e.g., 
intravesical immunotherapy or chemotherapy). From these 
who are most likely to benefit from intensification of care 
such as early radical cystectomy.
In patients with NMIBC, the probability of disease pro-
gression can be as high as 45% at five years [50]. Although 
it has been suggested that MM substaging might be help-
ful to identify high risk patients who are likely to suf-
fer from disease progression despite adequate intravesi-
cal therapy, available data quality has not been of high 
quality and prognostic tools have not included this valu-
able parameter [38, 51]. Martin-Doyle et al. evaluated 
(A)
(B)









Fig. 2  A Forest plots and funnel plot of studies investigating the asso-
ciation of T1a/b/c substaging system with disease progression (DP) 
and disease recurrence (DR) outcomes. B T1a/b/c substaging system 
RoB table, a Random sequence generation (selection bias). b Allo-
cation concealment (selection bias). c Blinding of participants and 
personnel (Performance bias.). d Blinding of outcome assessment 
(detection bias). e Incomplete outcome data (attrition bias). f Selec-
tive reporting (reporting bias); and adjustment for the effects of the 
following confounders. g Treatment modality. h Tumor grade. i CIS. 
j Multifocality. k T1 m/e substaging. l Tumor size. Green circles: low 
risk of bias and confounding, red circles: high risk of bias and con-
founding, yellow circles: unclear risk of bias and confounding. CI 
confidence interval, HR hazard ratio
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the prognosticators to improve selection criteria for early 
cystectomy in patients with high-grade T1 bladder cancer 
in a meta-analysis. The authors reported T1a/b substag-
ing system as a valuable prognosticator of oncological 
outcomes comparable with our study with pooled HR of 
1.81 (95%CI: 0.88–3.73) for DR and pooled HR of 3.55 
(95%CI: 1.92–6.56) for DP in 420 and 785 patients with 
high-grade T1 bladder cancer, respectively [51]. We con-
firmed that both MM invasion and tumor infiltration depth 
are strong predictors of disease progression after control-
ling for the effect of standard prognosticators. Indeed, 
patients harboring T1b/c or T1e in substaging system may 
benefit from early radical cystectomy as their tumor carries 
the biologic and clinical behavior of muscle-invasive blad-
der cancer [51]. In patients considered candidates for radi-
cal cystectomy, pretreatment imaging modalities includ-
ing magnetic resonance imaging and positron emission 
topography/computed tomography (CT) provide higher 
sensitivity and similar specificity compared to CT for 
detection of positive lymph nodes that might have a sig-
nificant impact on clinical decision-making process [52].
A consensus among pathologists is urgent to propose 
T1(or pT1) substaging systems as a prognosticator in TNM 
classification system and guidelines. MM is identified in 
12–83% of bladder biopsy specimen [53, 54]. Therefore, 
some studies proposed identification of large vessels of the 
vascular plexus as an alternative tumor extension marker 
in specimens without obvious MM [43, 46]. Moreover, 
although a cut-off point of 5 mm has been proposed in sev-
eral studies to define tumor infiltration depth, other stud-
ies have utilized other definitions [8, 35]. These discrep-
ancies between definitions may lead to low reproducibility 
and questionable validity. Standardization and prospective 
assessment in controlled studies is necessary.
(A)
(B)
Author, year a b c d e f g h i j k l




Fransen van de Putte 
2018
Fig. 3  A Forest plots and funnel plot of studies investigating the asso-
ciation of T1  m/e substaging system with disease progression (DP) 
and disease recurrence (DR) outcomes. B T1 m/e substaging system 
RoB table, a Random sequence generation (selection bias). b Allo-
cation concealment (selection bias). c Blinding of participants and 
personnel (Performance bias.). d Blinding of outcome assessment 
(detection bias). e Incomplete outcome data (attrition bias). f Selec-
tive reporting (reporting bias); and adjustment for the effects of the 
following confounders. g treatment modality. h tumor grade. i CIS. 
j Multifocality. k T1a/b/c substaging. l Tumor size. Green circles: 
low risk of bias and confounding, red circles: high risk of bias and 
confounding, yellow circles: unclear risk of bias and confounding. CI 
confidence interval, HR hazard ratio
1446 World Journal of Urology (2020) 38:1437–1449
1 3
According to our study, although substaging of T1(or 
pT1) disease is somewhat controversial and difficult to 
implement in all cases; the main advantage of this scoring 
system is to identify the high risk T1 bladder cancer patients 
who might benefit from more rigorous follow-up and ideally 
from more aggressive treatments which are appropriate for 
invasive bladder carcinoma.
This study is not without limitations. The majority of 
included studies in this systemic review were retrospective 
in design precluding robust conclusions about the prognostic 
value of T1(or pT1) substaging systems. Moreover, the het-
erogeneity of substaging systems was found in MM invasion 
and tumor infiltration depth systems as well as the outcomes 
assessed in the studies makes clear conclusions difficult. 
Indeed, further studies are needed to assess the prognostic 
value of T1(or pT1) substaging systems in patient counsel-
ling and risk-based selection of the personalized therapeutic 
modality.
Conclusion
We found that T1(or pT1) substaging systems are strong 
predictors of oncological outcomes (DR, DR). Although 
T1(or pT1) substaging systems are promising and can be 
used as an aid in determining the most appropriate treatment 
modality and intensity of follow-up, optimal T1(or pT1) sub-
staging system definition remains to be elucidated in future 
well-designed prospective studies.
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